Cargando…

BRAF(V600E) mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas

Frequency of a BRAF(V600E) mutation in anaplastic thyroid carcinoma, which is thought to be derived mainly from papillary carcinoma by multi-step carcinogenesis, is much lower than that in papillary carcinomas. To clarify this phenomenon, we analysed BRAF(V600E) mutation in 20 cases of anaplastic ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takano, T, Ito, Y, Hirokawa, M, Yoshida, H, Miyauchi, A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359941/ https://www.ncbi.nlm.nih.gov/pubmed/17453004 http://dx.doi.org/10.1038/sj.bjc.6603764

Ejemplares similares

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Poorly differentiated and anaplastic thyroid carcinomas: chromosomal and oligo-array profile of five new cell lines
por: Rodrigues, R F, et al.
Publicado: (2007)

BRAF(V600E) melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity
por: Whipple, C A, et al.
Publicado: (2014)

A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma
por: Lo, Michelle Chin I, et al.
Publicado: (2016)

UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas
por: Pallante, P, et al.
Publicado: (2005)

Promoter methylation of Wnt5a is associated with microsatellite instability and BRAF V600E mutation in two large populations of colorectal cancer patients
por: Rawson, J B, et al.
Publicado: (2011)

BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival
por: Hugdahl, Emilia, et al.
Publicado: (2016)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
por: Lang, Matthias, et al.
Publicado: (2023)

Decreased expression of haemoglobin beta (HBB) gene in anaplastic thyroid cancer and recovory of its expression inhibits cell growth
por: Onda, M, et al.
Publicado: (2005)

Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAF(V600E)-Mutated Anaplastic Thyroid Carcinoma
por: Wang, Jennifer R., et al.
Publicado: (2019)

Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma
por: Iyer, Priyanka C., et al.
Publicado: (2018)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

Preoperative BRAF(V600E) mutation detection in thyroid carcinoma by immunocytochemistry
por: Swan, Kristine Zøylner, et al.
Publicado: (2022)

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas
por: Moura, M M, et al.
Publicado: (2009)

Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations
por: Heinzerling, L, et al.
Publicado: (2013)

Risk and Prognostic Factors for BRAF(V600E) Mutations in Papillary Thyroid Carcinoma
por: Wei, Xiaojing, et al.
Publicado: (2022)

The BRAF(V600E) mutation analysis and risk stratification in papillary thyroid carcinoma
por: Scheffel, Rafael Selbach, et al.
Publicado: (2020)

Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours
por: Sheu, S-Y, et al.
Publicado: (2010)

Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines
por: Nobuhara, Y, et al.
Publicado: (2005)

Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma
por: Li, Qian, et al.
Publicado: (2017)

Mutations in Rb1 pathway-related genes are associated with poor prognosis in Anaplastic Astrocytomas
por: Bäcklund, L M, et al.
Publicado: (2005)

Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level
por: Sakaizawa, K, et al.
Publicado: (2012)

Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression
por: Lin, J, et al.
Publicado: (2011)

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
por: Yokota, T, et al.
Publicado: (2011)

Rare Manifestations of Anaplastic Thyroid Carcinoma: the Role of BRAF Mutation Analysis
por: Song, Young Shin, et al.
Publicado: (2017)

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients
por: Sun, Jian, et al.
Publicado: (2016)

KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer
por: Renaud, S, et al.
Publicado: (2015)

Detection of human parvovirus B19 in papillary thyroid carcinoma
por: Wang, J H, et al.
Publicado: (2008)

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
por: Schirripa, M, et al.
Publicado: (2015)

Oncofoetal fibronectin – a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma
por: Hesse, E, et al.
Publicado: (2005)

Detection of Plasma BRAF(V600E) Mutation Is Associated with Lung Metastasis in Papillary Thyroid Carcinomas
por: Kim, Bo Hyun, et al.
Publicado: (2015)

New insights into intranuclear inclusions in thyroid carcinoma: Association with autophagy and with BRAF(V600E) mutation
por: Schwertheim, Suzan, et al.
Publicado: (2019)

BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome
por: Saridaki, Z, et al.
Publicado: (2010)

PTEN loss is associated with follicular variant of Middle Eastern papillary thyroid carcinoma
por: Beg, S, et al.
Publicado: (2015)

A thyroid gland with over 30 foci of papillary thyroid carcinoma with activating BRAF V600E mutation
por: Pancer, Jill, et al.
Publicado: (2019)

Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS
por: Zuidervaart, W, et al.
Publicado: (2005)

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study
por: Board, R E, et al.
Publicado: (2009)

In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin
por: Batistatou, A, et al.
Publicado: (2007)

NrCAM, a neuronal system cell-adhesion molecule, is induced in papillary thyroid carcinomas
por: Górka, B, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_6la7oko6bkok0ltpaa9voo5tup